1. Home
  2. FONR vs VIGL Comparison

FONR vs VIGL Comparison

Compare FONR & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FONR
  • VIGL
  • Stock Information
  • Founded
  • FONR 1978
  • VIGL 2020
  • Country
  • FONR United States
  • VIGL United States
  • Employees
  • FONR N/A
  • VIGL N/A
  • Industry
  • FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • FONR Health Care
  • VIGL Health Care
  • Exchange
  • FONR Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • FONR N/A
  • VIGL 89.3M
  • IPO Year
  • FONR 1987
  • VIGL 2022
  • Fundamental
  • Price
  • FONR $13.54
  • VIGL $1.77
  • Analyst Decision
  • FONR
  • VIGL Strong Buy
  • Analyst Count
  • FONR 0
  • VIGL 5
  • Target Price
  • FONR N/A
  • VIGL $16.33
  • AVG Volume (30 Days)
  • FONR 9.4K
  • VIGL 163.1K
  • Earning Date
  • FONR 05-14-2025
  • VIGL 03-13-2025
  • Dividend Yield
  • FONR N/A
  • VIGL N/A
  • EPS Growth
  • FONR N/A
  • VIGL N/A
  • EPS
  • FONR 1.17
  • VIGL N/A
  • Revenue
  • FONR $101,570,089.00
  • VIGL N/A
  • Revenue This Year
  • FONR N/A
  • VIGL N/A
  • Revenue Next Year
  • FONR N/A
  • VIGL N/A
  • P/E Ratio
  • FONR $11.55
  • VIGL N/A
  • Revenue Growth
  • FONR N/A
  • VIGL N/A
  • 52 Week Low
  • FONR $13.27
  • VIGL $1.49
  • 52 Week High
  • FONR $20.34
  • VIGL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • FONR 39.33
  • VIGL 37.23
  • Support Level
  • FONR $13.70
  • VIGL $1.65
  • Resistance Level
  • FONR $14.19
  • VIGL $1.94
  • Average True Range (ATR)
  • FONR 0.34
  • VIGL 0.15
  • MACD
  • FONR 0.04
  • VIGL -0.01
  • Stochastic Oscillator
  • FONR 5.00
  • VIGL 22.51

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: